Effects of betel nut on cardiovascular risk factors in a rat model by Iqbal, Mohammad Perwaiz et al.
eCommons@AKU
Department of Biological & Biomedical Sciences Medical College, Pakistan
January 2012
Effects of betel nut on cardiovascular risk factors in
a rat model
Mohammad Perwaiz Iqbal
Aga Khan University, perwaiz.iqbal@aku.edu
Naseema Mehboobali
naseema.mehboobali@aku.edu
Ghulam Haider
Aga Khan University, ghulam.haider@aku.edu
Shahid Pervez
Aga Khan University, shahid.pervez@aku.edu
Iqbal Azam
Aga Khan University, iqbal.azam@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs
Part of the Biochemistry Commons
Recommended Citation
Iqbal, M. P., Mehboobali, N., Haider, G., Pervez, S., Azam, I. (2012). Effects of betel nut on cardiovascular risk factors in a rat model.
BMC Cardiovascular Disorders, 12, 94.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/468
RESEARCH ARTICLE Open Access
Effects of betel nut on cardiovascular risk factors
in a rat model
Mohammad Perwaiz Iqbal1*, Naseema Mehboobali1, Ghulam Haider1, Shahid Pervez2 and Iqbal Azam3
Abstract
Background: Areca nut (commonly known as betel nut) chewing has been shown to be associated with metabolic
syndrome and cardiovascular disease (CVD). The mechanism by which betel nut ingestion could lead to
development of CVD is not precisely known; however, dyslipidemia, hyperhomocysteinemia, hypertriglyceridemia
and inflammation could be some of the potential risk factors. This study was undertaken to investigate the effects
of two dosages of betel nut on homocysteinemia, inflammation and some of the components of metabolic
syndrome, such as hypertriglyceridemia, low HDL-cholesterol, obesity and fasting hyperglycemia in a rat model.
Methods: Thirty-six adult female Sprague Dawley rats, aged 10–12 weeks were divided into three equal groups.
Group-1 served as the control group (n = 12) and received water, whereas groups 2 and 3 were given water
suspension of betel nut orally in two dosages, 30 mg and 60 mg, respectively for a period of 5 weeks. At the end
of the fifth week, the animals were weighed and sacrificed, blood was collected and liver, kidney, spleen and
stomach were removed for histological examination.
Plasma/serum was analyzed for glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides,
homocysteine, folate, vitamin B12 and N-acetyl-β-D-glucosaminidase (NAG) – a marker of inflammation.
Results: When the mean concentration values of 3 groups were compared using one way ANOVA followed by
Tukey’s HSD-test, there was a significant increase in the concentration of total cholesterol (p = 0.04) in the group
receiving 30 mg/day betel nut compared to the control group. However, administration of a higher dose of betel
nut (60 mg/day) had no significant effect on the serum concentrations of glucose, total cholesterol,
HDL-cholesterol, LDL-cholesterol, and NAG. Histological examination of spleen revealed a dose-dependent
extramedullary hematopoiesis. No other remarkable change in the tissues (liver, kidney and stomach) was observed.
Mean serum/plasma levels of folate, vitamin B12 and homocysteine were not found to be significantly different in
all the groups. Betel nut ingestion had no effect on the mean body weights of rats.
Conclusions: Low dosage of betel nut is found to be associated with hypercholesterolemia. However, betel nut
ingestion is not associated with hyperhomocysteinemia, hypertriglyceridemia, hyperglycemia, inflammation and
increase in body weight in a rat model.
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Background
Areca nut (commonly known as betel nut) is the fourth
most commonly used addictive substance after caffeine,
nicotine and alcohol [1]. It is estimated that nearly 600
million people engage in betel nut chewing for stress re-
duction, feeling of well-being and alertness etc. [2].
However, its habitual use has significant adverse effects,
such as cancer of oral cavity, esophagus, stomach, liver,
prostate, cervix and lungs [3]. Areca nut chewing has
also been shown to increase the risk of many chronic
non-communicable diseases, such as obesity, type 2 dia-
betes mellitus, hypertension, hyperlipidemia, metabolic
syndrome and cardiovascular disease [4-8]. The mechan-
ism by which betel nut ingestion could lead to the devel-
opment of cardiovascular disease (CVD) is not precisely
known, however, folate and vitamin B12 deficiencies
leading to hyperhomocysteinemia [9], obesity [10],
hypertriglyceridemia [7], malabsorption of nutrients
[11], activation of sympathetic nervous system leading to
impaired baroreflex buffering [12] could be some of the
potential risk factors. Most of the work on the relation-
ship between CVD and betel nut chewing has been
through population based cohort studies where risk fac-
tors were assessed primarily on the basis of use and
non-use of betel nut. Very few studies have investigated
the effects of two different doses of betel nut in relation
to cardinal risk factors for CVD. The present study was
undertaken to investigate the effects of two different
dosages of betel nut on homocysteinemia, inflammation
and some of the components of metabolic syndrome,
such as hypertriglyceridemia, low HDL-cholesterol,
obesity and fasting hyperglycemia in a rat model.
Methods
Animals
In this animal study, 36 adult female Sprague Dawley
rats, aged 10–12 weeks with weights ranging from 162–
194 gm were experimented upon for a period of 35 days
(5 weeks). They were housed in the animal facility at the
Aga Khan University. The rats were allowed to have free
access to food and clean water under conditions of 12-
hour dark and light cycle and a temperature ranging
from 20-23°C. Food used was the standard diet for
rodents in pellet form. Rats were observed for signs of
abnormalities throughout the study. They were kept un-
treated for 2 days for complete acclimation to the la-
boratory conditions. The animals were divided into 3
groups, each group comprising of 12 animals. The group
1 served as the control group (n = 12) and received
water, whereas groups 2 and 3 were given water suspen-
sion of betel nut (orally) every day in the morning in
dosages 30 mg and 60 mg, respectively for a period of 5
weeks.
Drug treatment
For the rats in the two treatment groups, we selected 30
mg per day and 60 mg per day dosages of betel nut.
These dosages were based on the fact that the classical
doses of betel nut in humans have been reported to be
from 2–8 gm for various clinical conditions [13]. As-
suming an average human body weight of 55 kg, the
highest dose would be 145 mg/kg. Considering that the
mean body weight of rats during the study period
remains around 200 gm, the average dose of betel nut
would be approximately 30 mg per day. Moreover, it has
been shown that betel nut meal consumption in concen-
trations from 5-10% by albino rats for a period of 4
weeks produced no detectable pathological changes [14].
On the basis of these two lines of evidence, betel nut
doses of 30 mg and 60 mg were selected for the two
treatment groups (group 2 and group 3) respectively.
Preparation of betel nut suspension
Dried raw areca nut seeds were obtained from the
whole-sale market in Karachi to ensure that the material
in this study represents the main ingredient of various
forms in which it is usually consumed by the general
population. Dried nuts were ground into a powder form
using an electric grinder. Water suspensions of 30 mg/
mL and 60 mg/mL were prepared and placed on a Red
Rocker [Hoefer Scientific Instruments, San Francisco]
for 30 minutes for gentle mixing. Using a 3-mL syringe
and an oral gavage needle, 1 mL of betel nut suspension
was delivered in the lower end of the buccal cavity of
the rat.
Treatment period
One of the objectives of the study was to investigate the
effect of betel nut on weight gain in adolescent rats.
Since the maximum weight gain in adolescent female
Sprague Dawley rats is up to a period of 4–5 weeks [15],
it was decided that the treatment with betel nut would
be carried out for a period of 5 weeks, starting at the age
of 10–12 weeks. Moreover, a preliminary experiment
was also run which indicated that the maximum growth
of adult female Sprague Dawley rats was from a mean
age of 10 weeks to 16 weeks under the conditions of the
Animal Care facility of our University. Rats were
weighed in each group every week to determine any
change in body weight.
Scarification and collection of blood and tissues
At the end of 5 weeks of treatment, the animals were
weighed and anesthetized after being subjected to fasting
for 12 hours. Blood (3–4 mL) was collected from the
heart of each rat by cardiac puncture and transferred in
equal volumes to an EDTA tube and another tube with-
out any anti-coagulant. The rats were sacrificed by
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cervical dislocation while they were under the influence
of anesthesia [16]. Liver, kidney, spleen and stomach
were removed from each rat and fixed in 10% buffered
formalin for 24 hours. Plasma and serum were separated
immediately and stored at -200C until analysis. The
study had been approved by the Ethics Committee for
Research on Animals, Aga Khan University.
Measurements of biochemical parameters
Kits for fasting serum glucose, total cholesterol, high dens-
ity lipoprotein (HDL)-cholesterol, low density lipoprotein
(LDL)-cholesterol and triglycerides were obtained from
Roche Diagnostics, USA. Serum sample (200 μL) was ana-
lyzed on Cobas C III analyzer (Roche Diagnostics, USA).
The minimum limits of measurement for serum glucose,
total cholesterol, HDL-cholesterol, LDL-cholesterol and
triglycerides were 2.0 mg/dL, 9.7 mg/dL, 3.0 mg/dL, 3.9
mg/dL and 8.9 mg/dL, respectively.
Serum folate and vitamin B12 were analyzed by radio-
assays [17,18]. Both of these methods have been
described in detail in a recent publication [19]. Deter-
mination of plasma homocysteine was carried out using
a kit based on fluorescence polarization immunoassay
(Abbott Laboratories, Ltd, Pakistan) following the
instructions of the manufacturer. The limit of detection
of homocysteine by this assay is 4 μmol/L. N-acetyl-
beta-D-glucosaminidase (NAG)-a nonspecific marker of
inflammation was determined in serum samples using a
spectrofluorimetry based method of Whiting et al. [20].
One unit of NAG activity was defined as that which
released 1 μmole of 4-methylumbelliferone per minute
under assay conditions. This method has been described
in detail in a previous communication [21]. Serum ala-
nine aminotransferase (ALT) was analyzed spectrometri-
cally using a kit (RANDOX, UK) following the
manufacturer’s instructions. The lower detection limit of
this assay is 8.0 units/L.
Morphological studies
Liver, kidney, spleen and stomach immersed in 10% buf-
fered formalin for 24 hours were processed in a routine
fashion and embedded in paraffin. Serial sections (3-
5μm) were cut and stained with Hematoxylin and Eosin
(H & E). Slides were then examined under light micro-
scope by a histopathologist for any morphological
changes. Extramedullary erythropoiesis in splenic sec-
tions of rats from all three groups was done in a semi
quantitative method. Foci of extramedullary erythropoi-
esis were measured in millimeter using microstage and
ocular scale on Olympus BX51 microscope. The sums of
all foci showing extramedullary erythropoiesis were then
compared in three groups.
Statistical analysis
Descriptive results pertaining to the experimental groups
are reported as mean ± SD for body weight, lipid profile,
serum glucose, serum ALT, serum NAG , serum folate,
serum vitamin B12 and plasma homocysteine. Levels of
lipids, glucose, ALT, NAG, folate, vitamin B12 and homo-
cysteine in the three groups of rats were analyzed using
one way ANOVA because the assumptions of normality
and equality of variance were met. Significant associ-
ation by groups was then followed by Tukey’s HSD test
for multiple pair-wise comparisons. The differences in
mean body weights of rats over a period of 5 weeks by
experimental groups were compared using repeated
measures ANOVA. A p-value < 0.05 was considered sig-
nificant. Post-hoc power of the study was determined
using PASS 2008 software (NCSS, LLC 329 North 1000
East, Kaysville, Utah 84037, USA).
Results
Table 1 shows mean serum levels of total cholesterol,
LDL-cholesterol, HDL-cholesterol, triglycerides, serum
glucose, ALT and NAG in rats given betel nut suspen-
sion in water in dosages 30 mg and 60 mg per day. Only
total cholesterol concentration (p = 0.04) was found to
be significantly associated with the experimental groups
using one way ANOVA. The pair-wise comparison
showed a significant increase in the concentration of
total cholesterol (p = 0.04) in the group receiving 30
mg/day betel nut compared to the control group. How-
ever, administration of a higher dose of betel nut sus-
pension did not produce any significant effect on the
levels of serum glucose, serum HDL-cholesterol, LDL-
cholesterol, ALT and NAG compared to the control
group. Similarly, no significant associations in the mean
serum concentrations of folate, vitamin B12 and plasma
homocysteine for the three groups were observed
[Table 2].
Mean body weights of Sprague Dawley rats in each of
the three groups (control, 30 mg betel nut per day and
60 mg betel nut per day) at the start of the experiment
were nearly the same (Table 3). However, percent
increases in mean body weights in the control group
(group 1), group 2 (30 mg betel nut per day) and group
3 (60 mg betel nut per day) over a period of 5 weeks
were 10.2%, 12.2% and 13.6%, respectively. The mean
body weights (over the study period) when compared
using repeated measures ANOVA, were not found to be
significantly different among the 3 groups. This implies
that the effect of betel nut is the same across different
time intervals. The histological examination of the liver,
kidney and stomach showed no remarkable change.
There was no accumulation of fat in the liver of group 2
rats in spite of significantly high levels of cholesterol in
this group.
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Extramedullary hematopoiesis was, however, observed
in spleen in a dose dependent manner. The degree of
hematopoiesis (erythropoiesis with megakaryocytes) was
more pronounced in the group receiving 60 mg of betel
nut per day (Figure 1A and 1B) compared to few foci in
the group receiving 30 mg of betel nut per day
(Figure 1C), and none in the control group treated with
water (Figure 1D).
Discussion
Nearly 600 million people all around the world indulge in
betel nut chewing [2]. This habit is especially very com-
mon in 150 million South Asian populations [22]. In this
population a prevalence of CVD is found in almost epi-
demic proportions [23]. Recent reports have indicated an
association of CVD with betel nut chewing [6-8]. How-
ever, the results are conflicting about the effect of betel
nut chewing on various risk factors for CVD. The differ-
ences appear to be due to the fact that different popula-
tions could be using betel nut to varying degrees,
therefore, the daily rate of betel nut use would be more
important than a mere “use” or “non-use” information [7].
Moreover, some of the studies reporting low serum levels
of triglycerides and cholesterol were carried out using ex-
tract of betel nut in a rat model rather than a suspension
of the powdered nut [24]. However, a couple of large pro-
spective studies in Taiwan have shown a relationship be-
tween betel nut chewing and increased risk of CVD [6,7].
Our results in a rat model are novel in the sense
that we observed significantly high levels of serum
cholesterol at a dose of 30 mg betel nut powder per
day compared to a higher dose of the betel nut. This
suggests that very high consumption of betel nut
might not be associated with dyslipidemia due to the
inhibitory effect of high doses of betel nut on choles-
terol absorption [25]. This might be one explanation
why conflicting results have been reported by various
investigators.
A recently published study has shown a significant as-
sociation between betel nut chewing and systemic in-
flammation suggesting that it might be playing a role in
the development of systemic diseases at a later stage
[26]. Plasma NAG is a non-specific marker of inflamma-
tion. Its concentration in plasma increases in a number
of inflammatory conditions [27]. Ingestion of betel nut
in the present study did not produce any significant
change in the concentration of plasma NAG in rats indi-
cating that betel nut in doses upto 60 mg/day does not
produce any noticeable inflammation in rats. This is fur-
ther substantiated by the absence of inflammatory cells
upon the histological examination of liver, kidney, spleen
and stomach biopsies from various groups of rats
(photograph of only spleen is shown in Figure 1). More-
over, our results pertaining to serum levels of ALT also
show that liver function does not appear to be compro-
mised by betel nut ingestion in a rodent model.
Table 1 Effect of betel nut on lipid profile, serum glucose, alanine aminotransferase and N-acetyl-β-D-glucosaminidase
Variable Group 1 (Control) Group 2 (30 mg betel nut/day) Group 3 (60 mg betel nut/day) P-value
n = 12 n = 12 n = 12
Mean ± SD
Total cholesterol (mg/dL) 70.7 ± 15.3 92.4 ± 23.0* 80 ± 21.7 0.04
LDL-cholesterol (mg/dL) 11.6 ± 4.9 14.3 ± 6.0 11.7 ± 6.0 0.43
HDL-cholesterol (mg/dL) 60.0 ± 11.9 73.3 ± 15.7 66.7 ± 16.4 0.11
Triglycerides (mg/dL) 56.3 ± 14.0 82.3 ± 44.8 60 ± 36.6 0.14
Glucose (mg/dL) 92.7 ± 30.5 85.7 ± 36.0 82.6 ± 24.8 0.72
ALT (U/L) 63.0 ± 25.7 56.0 ±19.2 42.0 ± 15.4 0.10
NAG (U/L) 7.0 ± 1.0 7.0 ± 1.7 7.0 ± 1.0 0.99
ALT = Alanine aminotransferase.
NAG = N-acetyl-β-D-glucosaminidase.
*p = 0.04; one way ANOVA followed by Tukey’s HSD test were used to compare mean values.
Table 2 Effect of betel nut on serum folate, serum vitamin B12 and plasma homocysteine
Variable Group 1 (Control) Group 2 (30 mg betel nut/day) Group 3 (60 mg betel nut/day) P-value
n = 12 n = 12 n = 12
Mean ± SD
Serum folate (ng/mL) 26.6 ± 9.6 32.0 ± 11.8 27.7 ± 8.9 0.42
Serum vitamin B12 (pg/mL) 284.0 ± 93.5 305.0 ± 76.8 295.8 ± 98.0 0.85
Plasma homocysteine (μmol/L) 7.8 ± 1.3 8.5 ± 3.1 7.2 ±2.0 0.41
Note: Mean values in 3 groups were compared using one way ANOVA followed by Tukey’s HSD test; p-value < 0.05 was considered significant.
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Betel nut chewing has also been found to be associated
with increased risk of developing diabetes mellitus [28].
However, in the present study, ingestion of betel nut
upto a dose of 60 mg/day had no effect on fasting glu-
cose levels in a rodent model. This also indicates that
rodents might be responding to betel nut in a different
manner.
Mean concentrations of serum folate, vitamin B12 and
plasma homocysteine remained similar across the 3
groups (Table 2). These findings are not in line with the
reported association of folate deficiency and hyperhomo-
cysteinemia with betel nut use in Bangladeshi human
subjects [9]. The difference may be because of adequate
availability of folate in the rodent diet. It has been
reported that chewing betel quid or areca nut could de-
crease body weight in hamsters over a period of 4
months [29]. However, in the present study we did not
find any significant difference in the total body weight of
rats among the control group of rats, as well as those
treated with betel nut over a period of 5 weeks. This
shows that betel nut ingestion over a relatively short
period of time has no adverse effect on the weight of
growing rats.
The effect of betel nut on various body organs merits
some discussion. Betel nut chewing results in exposure
to its various alkaloid derivatives such as N-nitroso-
compounds and polyphenols which could adversely
affect various organs of the body such as stomach, liver,
lung and pancreas [1]. Results of the histological exam-
ination of stomach, liver, spleen and kidney revealed no
remarkable change after 5 weeks of betel nut administra-
tion except increased extramedullary hematopoiesis in
Figure 1 Photomicrograph of rat spleen treated with betel nut at two different doses. (1A) Section of spleen from a rat treated with
60 mg/day dose of betel nut for 5 weeks. Numerous foci of extramedullary erythropoiesis with megakaryocytes (marked by arrow). H & E, Mag:
20X. (1B) Photomicrograph IA at a higher magnification (Mag: 40X). (1C) Section of spleen from a rat treated with 30 mg/day dose of betel nut
for 5 weeks. Few foci of extrameduallary hematopoiesis; megakaryote marked by arrow. H & E, Mag: 20X. (1D) Section of a spleen from an
age-matched control rat treated with water. No extramedullary hematopoiesis is seen. H & E, Mag: 20X.
Table 3 Mean body weights of three groups of rats receiving betel nut or placebo for 5 weeks
Group n Body wt at
Day 1 (gm)
Body wt at
Day 8 (gm)
Body wt at
Day 15 (gm)
Body wt at
Day 22 (gm)
Body wt at
Day 29 (gm)
Body wt at
Day 36 (gm)
Mean ± SD
Control (Placebo) 12 168.5 ± 10.1 177.7 ± 10.2 182.1 ± 7.2 184.2 ± 9.4 186.7 ± 8.5 185.7 ± 9.8
Betel nut (30 mg/day) 12 167.0 ± 13.3 177.8 ± 14.5 184.8 ± 13.5 187.5 ± 12.6 190.1 ± 14.9 187.5 ±13.9
Betel nut (60 mg/day) 12 167.1 ± 10.2 177.7 ± 10.4 182.2 ±10.6 184.9 ± 10.0 189.8 ± 7.1 189.9 ± 8.5
Note: Mean body weights of rats among the 3 groups over a period of 5 weeks were compared using repeated measures ANOVA; F-statistic for the group =
0.122, p-value = 0.885; F-statistic for days = 27.529, p-value = < 0.001; F-statistic for the interaction of groups and days = 0.788, p-value = 0.578.
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spleen. Extramedullary hematopoiesis tends to be
decreased in adult animals, but can increase in cases of
anemia, inflammation or decreased production by bone
marrow [30]. Our observation that there is a dose-
dependent increase in extramedullary hematopoiesis in
spleen due to betel nut suggests that higher doses of this
natural product could be adversely affecting bone mar-
row function. However, this notion needs to be further
explored.
The results of the study need to be evaluated within
the context of certain limitations. Quantification of main
alkaloids in the betel nut suspension for the intervention
group was not carried out. This has been a limiting fac-
tor in discussing our results in the light of the main
alkaloids present in the local betel nut. Moreover, the
sample size in this study was relatively small. The post-
hoc power of the study was calculated and found to be
in the range 5% (NAG) to 99.2% (triglycerides). How-
ever, power turned out to be sufficient (85%) for the sig-
nificant variable (total cholesterol concentration) in this
study. We are also mindful of the fact that betel nut is
normally chewed by humans. However, in this study, in
order to ensure complete ingestion of the nut in two dif-
ferent dosages, we administered a water suspension of
betel nut in the buccal cavities of rats. This indeed was a
limitation; yet, our focus in this study was on determin-
ing the systemic effects of betel nut via gut absorption.
Furthermore, the fact that levels of serum cholesterol in
rats receiving a high dose of betel nut (60 mg/day)
were lower than expected could be attributed to the
inhibition of two enzymes involved in cholesterol ab-
sorption, such as pancreatic cholesterol esterase and in-
testinal acyl-CoA:cholesterol acyltransferase, as reported
earlier in a rat model [25]. One possibility could be a
dose-dependent effect; though the activity of these two
enzymes was not monitored in the present study to in-
vestigate this hypothesis.
Conclusions
The results of the investigation revealed that hyperchol-
esterolemia was caused by a relatively small dose (30
mg/day) of betel nut in a rat model. This metabolic
change was not accompanied by any significant alter-
ation in inflammation, serum levels of HDL-cholesterol,
LDL-cholesterol, triglycerides, ALT, fasting glucose,
homocysteinemia and body weight. However, the find-
ings suggest that even small doses of betel nut could
have detrimental effects. Further studies on a relatively
narrowed down range of dosages of betel nut would be
required to find out the precise dose at which the dele-
terious effects of this nut begin to manifest. It is impera-
tive that betel nut chewing must be investigated in
populations which are at a greater risk of developing
CVD.
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